Skip to main content

RXi, UMMS Receive Massachusetts Life Sciences Center Funding for ALS Work

Premium

RXi Pharmaceuticals said this week that its planned collaboration with the University of Massachusetts Medical School to develop an RNAi-based treatment for amyotrophic lateral sclerosis has been selected for matching funding from the Massachusetts Life Sciences Center.

The funding is worth $250,000 per year for two years and will be matched dollar for dollar by RXi. The award is still subject to a formal agreement between RXi and UMMS.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.